Esophageal Cancer: Should Gender Be Considered as an Influential Factor for Patient Safety in Drug Treatment?

Fengxia Liu; Helin Feng; Sumin Guo; Yuhan Chen; Qingyi Liu; Feng Wu; Weikuan Gu; Baoen Shan

doi:10.1155/2019/6340567

Esophageal Cancer: Should Gender Be Considered as an Influential Factor for Patient Safety in Drug Treatment?

J Oncol. 2019 May 23:2019:6340567. doi: 10.1155/2019/6340567. eCollection 2019.

Authors

Fengxia Liu^{1

2}, Helin Feng^{1

2}, Sumin Guo^{2

3}, Yuhan Chen⁴, Qingyi Liu¹, Feng Wu⁵, Weikuan Gu^{2

6}, Baoen Shan¹

Affiliations

¹ The Fourth Hospital, Hebei Medical University, 12 Jiankang Road, Shijiazhuang, Hebei Province 050011, China.
² Department of Orthopedic Surgery and BME-Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
³ Department of Oncology, Chest Hospital of Hebei Province, Shijiazhuang, Hebei 050041, China.
⁴ Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
⁵ The 2nd Affiliated Hospital of Harbin Medical University, No. 7 building, Baojian Road, Harbin, Heilongjiang 161005, China.
⁶ Research Service, Veterans Affairs Medical Center, 1030 Jefferson Avenue, Memphis, TN 38104, USA.

Abstract

Aim: Analyze the gender difference of esophageal cancer patients in response to drug treatment.

Methods: All publications on clinical trials were collected from PubMed, Scopus, and PMC. Each publication was examined to determine whether the publication is a clinical trial and whether data on gender difference were reported.

Results: Selected from a total of 191 publications, data from 7 trials with a total of 2041 patients were evaluated for gender differences. These clinical trials involve different drugs and disease phenotype. A significant difference was obtained between male and female groups from Student's t-test. There is no conclusive result on age, ethnicity, tumor size, and drug influence.

Conclusions: Gender difference in response to treatment potentially most likely exists in esophageal cancer patients, regardless of age, race, and drugs.

Publication types

Review